Jian Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jian Chen has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Jingfang Mao
Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai Key Laboratory of radiation oncology (20dz2261000), Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China
3 shared publications Kai-Liang Wu
Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai Key Laboratory of radiation oncology (20dz2261000); Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Fudan University Cancer Hospital, Shanghai, China
2 shared publicationsNingyi Ma
Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai Key Laboratory of radiation oncology (20dz2261000); Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Fudan University Cancer Hospital, Shanghai, China
2 shared publications- Chang Chen
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China
1 shared publication Guo-Liang Jiang
Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai Key Laboratory of radiation oncology (20dz2261000); Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Fudan University Cancer Hospital, Shanghai, China
1 shared publication- Guo-Liang Jiang
Shanghai Key Laboratory of Radiation Oncology (20dz2261000), Shanghai, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China; Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 20 January 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (6) , 3849-3861
Impact of carbon-ion radiotherapy on tumor hypoxia detected by 18F-FMISO PET/CT in locally advanced non-small cell lung cancer
Purpose The study aimed to assess the impact of carbon-ion radiotherapy (CIRT) on intratumoral hypoxia in patients with locally advanced non-small cell lung cancer (LA-NSCLC) and the predictive value of 18F-fluoromisonidazole (FMISO) and 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). Methods We retrospectively analyzed patients with stage IIB–IIIC NSCLC treated with CIRT who underwent baseline 18F-FMISO and 18F-FDG PET/CT and post-CIRT 18F-FMISO PET/CT. Regions of interest (ROIs) with a diameter ≥ 3 cm were analyzed. An ROI was defined as hypoxia with a tumor-to-muscle ratio (TMR) ≥ 1.4 on 18F-FMISO PET/CT. Survival outcomes were evaluated using Kaplan-Meier curves, and group comparisons were performed using Log-rank test. Results Thirty-seven eligible patients with 42 ROIs were included. Significant reductions in all 18F-FMISO parameters were observed after CIRT. ROIs with or without pre-CIRT hypoxia achieved similar local control (LC, with vs. without hypoxia: 75.5% vs. 85.5%, p = 0.799). The overlap ratios of hypoxic volumes between pre-/post-CIRT were 58.13%–81.34%. The combination of 18F-FDG uptake and post-CIRT hypoxia status demonstrated the strongest predictive value for LC (high vs. low uptake: 46.8% vs. 95.8%, p = 0.0004) with the highest area under the receiver operating characteristic curve (0.783, p = 0.01) among all evaluated combinations. Conclusion Tumor hypoxia detected by 18F-FMISO PET/CT was significantly decreased after CIRT in patients with LA-NSCLC. Similar LC was achieved in patients with or without pre-CIRT hypoxia, while post-CIRT hypoxia clearance resulted in a non-significant trend toward improved LC. Combining 18F-FMISO and 18F-FDG PET/CT might provide enhanced prognostic value. Further investigation is warranted to explore individualized CIRT dose painting strategies guided by multi-tracer PET/CT imaging.
- 20 January 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (6) , 3849-3861
Open AccessImpact of carbon-ion radiotherapy on tumor hypoxia detected by 18F-FMISO PET/CT in locally advanced non-small cell lung cancer
Purpose The study aimed to assess the impact of carbon-ion radiotherapy (CIRT) on intratumoral hypoxia in patients with locally advanced non-small cell lung cancer (LA-NSCLC) and the predictive value of 18F-fluoromisonidazole (FMISO) and 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). Methods We retrospectively analyzed patients with stage IIB–IIIC NSCLC treated with CIRT who underwent baseline 18F-FMISO and 18F-FDG PET/CT and post-CIRT 18F-FMISO PET/CT. Regions of interest (ROIs) with a diameter ≥ 3 cm were analyzed. An ROI was defined as hypoxia with a tumor-to-muscle ratio (TMR) ≥ 1.4 on 18F-FMISO PET/CT. Survival outcomes were evaluated using Kaplan-Meier curves, and group comparisons were performed using Log-rank test. Results Thirty-seven eligible patients with 42 ROIs were included. Significant reductions in all 18F-FMISO parameters were observed after CIRT. ROIs with or without pre-CIRT hypoxia achieved similar local control (LC, with vs. without hypoxia: 75.5% vs. 85.5%, p = 0.799). The overlap ratios of hypoxic volumes between pre-/post-CIRT were 58.13%–81.34%. The combination of 18F-FDG uptake and post-CIRT hypoxia status demonstrated the strongest predictive value for LC (high vs. low uptake: 46.8% vs. 95.8%, p = 0.0004) with the highest area under the receiver operating characteristic curve (0.783, p = 0.01) among all evaluated combinations. Conclusion Tumor hypoxia detected by 18F-FMISO PET/CT was significantly decreased after CIRT in patients with LA-NSCLC. Similar LC was achieved in patients with or without pre-CIRT hypoxia, while post-CIRT hypoxia clearance resulted in a non-significant trend toward improved LC. Combining 18F-FMISO and 18F-FDG PET/CT might provide enhanced prognostic value. Further investigation is warranted to explore individualized CIRT dose painting strategies guided by multi-tracer PET/CT imaging.
- Open Access
- 26 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Development and validation of NTCP models for predicting acute esophagitis in carbon ion radiotherapy for thoracic malignancies
Acute esophagitis (AE) is a common toxicity following carbon ion radiotherapy (CIRT) for thoracic malignancies (TM). Despite CIRT’s physical advantag
- 26 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessDevelopment and validation of NTCP models for predicting acute esophagitis in carbon ion radiotherapy for thoracic malignancies
Acute esophagitis (AE) is a common toxicity following carbon ion radiotherapy (CIRT) for thoracic malignancies (TM). Despite CIRT’s physical advantag
- Open Access
- 25 January 2019
- Published by Springer Nature in Radiation Oncology
- Vol. 14 (1) , 16
Early stage non-small cell lung cancer treated with pencil beam scanning particle therapy: retrospective analysis of early results on safety and efficacy
To evaluate the safety and efficacy of particle therapy (PT) using pencil beam scanning (PBS) technique for early stage non-small cell lung cancer (NSCLC). From 08/2014 to 03/2018, 31 consecutive patients with sum of the longest diameters of primary tumor and hilar lymph node < 5 cm, N0–1, M0 NSCLC treated with PT were retrospectively analyzed. Gating/active breathing control techniques were used to control tumor motion in 20 and 7 patients. PBS-based proton radiotherapy (PRT) or carbon ion radiotherapy (CIRT) plans were designed via Syngo® planning system. PRT, PRT + CIRT boost, and CIRT were used in 6, 6 and 19 patients, respectively. Prescriptions were categorized to 3 levels: 5–7.5 GyE * 8–10 Fx, 4–5 GyE * 15–16 Fx and 2.25–3.5 GyE * 20–31 Fx. Thirty-one patients (20 males and 11 females) with a median age of 71 (50–80) years were enrolled with a median follow-up time of 12.1 (2.9–45.2) months. Fourteen were adenocarcinomas, 7 squamous cell carcinomas, 4 non-specified NSCLC and 6 had no histological diagnosis (4/6 had previous resected lung cancer). The median tumor size was 3.1 (1.1–4.7) cm. No grade 4–5 toxicities were observed. One patient experienced grade 3 (per the Common Terminology Criteria for Adverse Events version 4.03) radiation-induced lung injury (RILI) at 6.7 months from radiation started. Grade 2 acute toxicities included hematological toxicities (5 cases), RILI (2), plural pain (1) and dermatitis (1). Grade 2 late toxicities included RILI (3) and asymptomatic rib fracture (1). Three patients had progressed disease at 4.0~10.6 months after the initiation of PT. One experienced local failure with simultaneous distant failure and died of brain metastasis at 10.8 months; one developed regional and distant failure and died of lung infection at 8.7 months; the other experienced isolated distant failure only and his disease was well controlled after salvage systemic therapy. The estimated rates of progression-free survival, local control, cause-specific survival and overall survival at 1, 2 years were 85.5% and 85.5%, 95.2% and 95.2%, 95.0% and 95.0%, 90.7% and 90.7%, respectively. PBS-based PT appears safe and effective for early stage NSCLC. Further follow-up and investigation is warranted. ISRCTN, ISRCTN78973763. Registered 14 August 2018- Retrospectively registered, http://www.isrctn.com/ISRCTN78973763 .
- 25 January 2019
- Published by Springer Nature in Radiation Oncology
- Vol. 14 (1) , 16
Open AccessEarly stage non-small cell lung cancer treated with pencil beam scanning particle therapy: retrospective analysis of early results on safety and efficacy
To evaluate the safety and efficacy of particle therapy (PT) using pencil beam scanning (PBS) technique for early stage non-small cell lung cancer (NSCLC). From 08/2014 to 03/2018, 31 consecutive patients with sum of the longest diameters of primary tumor and hilar lymph node < 5 cm, N0–1, M0 NSCLC treated with PT were retrospectively analyzed. Gating/active breathing control techniques were used to control tumor motion in 20 and 7 patients. PBS-based proton radiotherapy (PRT) or carbon ion radiotherapy (CIRT) plans were designed via Syngo® planning system. PRT, PRT + CIRT boost, and CIRT were used in 6, 6 and 19 patients, respectively. Prescriptions were categorized to 3 levels: 5–7.5 GyE * 8–10 Fx, 4–5 GyE * 15–16 Fx and 2.25–3.5 GyE * 20–31 Fx. Thirty-one patients (20 males and 11 females) with a median age of 71 (50–80) years were enrolled with a median follow-up time of 12.1 (2.9–45.2) months. Fourteen were adenocarcinomas, 7 squamous cell carcinomas, 4 non-specified NSCLC and 6 had no histological diagnosis (4/6 had previous resected lung cancer). The median tumor size was 3.1 (1.1–4.7) cm. No grade 4–5 toxicities were observed. One patient experienced grade 3 (per the Common Terminology Criteria for Adverse Events version 4.03) radiation-induced lung injury (RILI) at 6.7 months from radiation started. Grade 2 acute toxicities included hematological toxicities (5 cases), RILI (2), plural pain (1) and dermatitis (1). Grade 2 late toxicities included RILI (3) and asymptomatic rib fracture (1). Three patients had progressed disease at 4.0~10.6 months after the initiation of PT. One experienced local failure with simultaneous distant failure and died of brain metastasis at 10.8 months; one developed regional and distant failure and died of lung infection at 8.7 months; the other experienced isolated distant failure only and his disease was well controlled after salvage systemic therapy. The estimated rates of progression-free survival, local control, cause-specific survival and overall survival at 1, 2 years were 85.5% and 85.5%, 95.2% and 95.2%, 95.0% and 95.0%, 90.7% and 90.7%, respectively. PBS-based PT appears safe and effective for early stage NSCLC. Further follow-up and investigation is warranted. ISRCTN, ISRCTN78973763. Registered 14 August 2018- Retrospectively registered, http://www.isrctn.com/ISRCTN78973763 .